Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, reviewing concerns about risks of aggressive treatment of bulky locally advanced NSCLC and potential management strategies.
Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, covering management approaches for a stage IIIB locally advanced NSCLC with ambiguous imaging results after chemo and radiation were completed.
Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing current evidence and challenges of post-operative treatments for early stage NSCLC in elderly and/or frail patients.
Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, answers questions about what treatments to recommend after first line therapy for advanced NSCLC and when they should be pursued.
Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.
Dr. Howard (Jack) West, medical oncologist, President & CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).
Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.
Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.
Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.
Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of man with an isolated brain metastasis being considered for curative therapy.
Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.
Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.
Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of a relatively fit man with malignant pleural mesothelioma.
Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.
Case discussion of management options for an elderly man with slowly progressing BAC, with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute.
Dr. Kristin Manning, expert radiologist at Seattle Radiology, discusses work on lung cancer screening, the features of a pulmonary nodule that raise and lower suspicion for lung cancer, and other aspects of initial and follow-up imaging for lung cancer.
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses new approaches in molecular profiling of lung cancers.
Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the basic subtypes of non-small cell lung cancer (NSCLC), methods of interpreting NSCLC histology, and the changing importance of pathology in NSCLC management.
Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on first line chemo standards and the transition to maintenance therapy.
Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on never-smokers and EGFR mutation testing.
This slide presentation by Dr. Julie Brahmer, medical oncologist and lung cancer expert at Johns Hopkins University, reviews the factors to be considered in the selection of agents and timing of treatments given after first line therapy for advanced NSCLC.
This slide presentation by Dr. George Simon, Director of Thoracic Oncology at Fox Chase Cancer Center, describes emerging molecular variables that are being studied to optimize individualized selection of systemic treatments for NSCLC.
This slide presentation by Dr. Alan Sandler, medical oncologist and Division Chief of Hematology/Oncology at Oregon Health and Science University, provides an introduction to our current first line treatment options for metastatic NSCLC.
This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.
This slide presentation by Dr. Shirish Gadgeel, medical oncologist at Wayne State University, discusses the considerations and evidence about whether locally advanced (Stage III) NSCLC should be managed surgically or with chemo/radiation alone.
